IgA肾病:凝集素途径及其靶向治疗意义
本综述聚焦IgA肾病中凝集素途径的作用。肾活检显示高达50%患者肾小球有甘露糖结合凝集素与IgA1共沉积,且与更严重的肾小球损伤、蛋白尿和血尿相关。新研究提示凝集素途径可能促进小管间质纤维化,collectin-11是关键介质;综述总结了支持该途径作用的证据并探讨抑制凝集素途径的治疗可能。
要点
- 高达50%的IgA肾病患者肾小球中有甘露糖结合凝集素与IgA1共沉积。
- 凝集素途径模式识别分子沉积与更严重肾小球损伤、蛋白尿和血尿相关。
- 凝集素途径可能参与小管间质纤维化,collectin-11是关键介质。
核心结论
- 凝集素途径是IgA肾病肾损伤的关键介质和潜在治疗靶点,但综述未给出具体治疗推荐。
研究设计与样本
- 综述,总结支持凝集素途径在IgA肾病中作用的科学和临床证据,并探讨抑制该途径的治疗可能。
主要发现
- 肾活检一致显示高达50%的IgA肾病患者肾小球中有甘露糖结合凝集素与IgA1共沉积。
- 凝集素途径模式识别分子肾小球沉积与更严重肾小球损伤、更严重蛋白尿和血尿相关。
- 新研究提示凝集素途径可能参与IgA肾病小管间质纤维化,collectin-11是关键介质。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients with immunoglobulin A nephropathy (IgAN) progress to kidney failure even with optimal supportive care. An improved understanding of the pathophysiology of IgAN in recent years has led to the investigation of targeted therapies with acceptable tolerability that may address the underlying causes of IgAN or the pathogenesis of kidney injury. The complement system-particularly the lectin and alternative pathways of complement-has emerged as a key mediator of kidney injury in IgAN and a possible target for investigational therapy. This review will focus on the lectin pathway. The examination of kidney biopsies has consistently shown glomerular deposition of mannan-binding lectin (1 of 6 pattern-recognition molecules that activate the lectin pathway) together with IgA1 in up to 50% of patients with IgAN. Glomerular deposition of pattern-recognition molecules for the lectin pathway is associated with more severe glomerular damage and more severe proteinuria and hematuria. Emerging research suggests that the lectin pathway may also contribute to tubulointerstitial fibrosis in IgAN and that collectin-11 is a key mediator of this association. This review summarizes the growing scientific and clinical evidence supporting the role of the lectin pathway in IgAN and examines the possible therapeutic role of lectin pathway inhibition for these patients.
引用
- Barratt J, Lafayette RA, Zhang H, et al. IgA nephropathy: the lectin pathway and implications for targeted therapy. Kidney Int. 2023. PMID: 37263354. doi:10.1016/j.kint.2023.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。